Jonathan Licht, M.D., named editor-in-chief of Blood Neoplasia

The American Society of Hematology (ASH) has selected Jonathan D. Licht, M.D., director of the UF Health Cancer Center, as the inaugural editor-in-chief of one of the newest additions to the Blood Journals portfolio, Blood Neoplasia. He was selected by the ASH Executive Committee after a competitive international search.

Jonathan D. Licht, M.D.

Blood Neoplasia, launching in 2024 with submissions opening later this month, will be a peer-reviewed, open access journal that publishes high-quality original research in specialized blood disease areas. Blood Neoplasia will publish research focused on hematologic malignancies and associated disorders, including leukemia, lymphoma, multiple myeloma and more. Along with another new journal, Blood VTH, these new journals complement ASH’s existing publications, Blood and Blood Advances, to meet the demands of the growing field of hematology and aim to foster community in these areas of research.  

Licht is a physician-scientist with a long interest in epigenetic deregulation in blood malignancies who has authored more than 200 publications with 32,000 citations. In June 2023, under his leadership, the UF Health Cancer Center became the 72nd National Cancer Institute-designated cancer center. Previously, Licht served as chief of hematology/oncology at Northwestern University and Mount Sinai. He has served as an ASH Councilor and as co-director of the ASH/European Hematology Association Translational Training in Hematology program.

“I look forward to serving as editor-in-chief of Blood Neoplasia and showcasing high-quality, rigorous research in the malignant hematology space,” Licht said. “I’ve worn many hats throughout my career as both a researcher and a practicing oncologist, which is why I aim to publish exciting, clinically relevant new research in Blood Neoplasia.”

Read more about the new journals.

Dr. Licht shared his vision for Neoplasia in a podcast episode. Listen below.

NCI Cancer Center badge